Observational studyClinical transplantation2026
Lung Transplantation in Rheumatoid Arthritis Related Interstitial Lung Disease: Risk Factors and Mortality in a Universal Health Care System.
Observational study in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDespite therapy, some patients with rheumatoid arthritis related interstitial lung disease (RA-ILD) require lung transplantation for progressive disease. We aimed to identify factors associated with lung transplantation and post-transplantation survival in RA-ILD.
methodsWe performed a retrospective observational cohort study using data from Ontario, Canada between 2003 and 2022. RA-ILD patients were identified from the Ontario RA Database. We used a cause-specific hazards model, considering the competing risk of death, to identify factors associated with lung transplantation. A Cox proportional hazards model was used to evaluate post-transplant survival.
resultsAmong 6470 RA-ILD patients, 77 (1.2%) underwent lung transplantation, equating to 2.40 transplants per 1000 person years. The median time to transplant was 3.7 years. Younger age [HR 0.93 per increasing year (95%CI 0.91-0.95), p < 0.0001], male sex [HR 2.40 (95%CI 1.523.78), p = 0.0002], and comorbid diabetes [HR 1.70 (95%CI 1.06-2.73), p = 0.003], congestive heart failure [HR 1.87 (95%CI 1.15-3.04), p = 0.01] and COPD [HR 2.14 (95%CI 1.25-3.68), p = 0.006] were associated with transplantation. The median survival following transplantation was 4.3 years.
conclusionLung transplantation is an uncommon, but important therapy for RA-ILD. Select comorbidities are associated with lung transplantation. Post-transplant survival among RA-ILD patients in Ontario was comparable to that reported elsewhere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.